Zacks Investment Research on MSN
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago. These ...
Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter can be downloaded here. In the quarter, Minot Light generated solid returns ...
MarketBeat on MSN
Lucid Diagnostics Q1 earnings call highlights
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 ...
View Lucid Diagnostics Inc. LUCD stock quote prices, financial information, real-time forecasts, and company news from CNN.
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.
Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and ...
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results